AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

NCT01018069 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
60
Enrollment
INDUSTRY
Sponsor class

Stopped Failed to reach endpoints

Conditions

Interventions

Sponsor

Aegera Therapeutics